Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Invested Capital (2022 - 2025)

Corvus Pharmaceuticals has reported Invested Capital over the past 4 years, most recently at $71.8 million for Q3 2025.

  • Quarterly results put Invested Capital at $71.8 million for Q3 2025, up 478.35% from a year ago — trailing twelve months through Sep 2025 was $71.8 million (up 478.35% YoY), and the annual figure for FY2024 was $32.6 million, down 15.81%.
  • Invested Capital for Q3 2025 was $71.8 million at Corvus Pharmaceuticals, down from $80.2 million in the prior quarter.
  • Over the last five years, Invested Capital for CRVS hit a ceiling of $89.7 million in Q1 2022 and a floor of $12.4 million in Q3 2024.
  • Median Invested Capital over the past 4 years was $49.5 million (2023), compared with a mean of $53.5 million.
  • Biggest five-year swings in Invested Capital: plummeted 71.98% in 2024 and later soared 478.35% in 2025.
  • Corvus Pharmaceuticals' Invested Capital stood at $56.1 million in 2022, then tumbled by 31.06% to $38.7 million in 2023, then dropped by 15.81% to $32.6 million in 2024, then soared by 120.36% to $71.8 million in 2025.
  • The last three reported values for Invested Capital were $71.8 million (Q3 2025), $80.2 million (Q2 2025), and $49.3 million (Q1 2025) per Business Quant data.